The goal of my research program is to work with knowledge users to inform national and international decisions about optimal infectious disease control and prevention strategies in the context of limited resources, and to provide better modeling tools for policy decisions. My team and I develop state-of-the-art transmission-dynamic models, analyze large population-level datasets, and use epidemiology and health economics to estimate the effectiveness and cost-effectiveness of infectious disease control and prevention strategies at the population-level and within vulnerable or at-risk groups.
Marc Brisson participated to the Stakeholder Collaborative Meeting on Strategic Prioritization for HPV Vaccination in Lao People’s Democratic Republic (Lao PDR) held on May 26, 2025, in Vientiane, Lao PDR. He presented the HPV-ADVISE model and our modeling approach. [ Meeting Report ]
Marc Brisson presented modeling results at the Stakeholder Collaborative Meeting on Preliminary Findings of the Strategic Prioritization for HPV Vaccination in Thailand, in Bangkok, Thailand, May 23, 2025.
Marc Brisson was honored at the Virtuoses de la santé 2025 ceremony, organized by the Faculty of Medicine at Université Laval, Québec, Canada. This tribute recognized Marc’s appointment to a Tier 1 Canada Research Chair. As part of the recognition, he received a personalized illustration—a symbolic gesture highlighting his contribution to the advancement of medical research.
Marc Brisson was invited as faculty to the 25th Advanced Course of Vaccinology (ADVAC) that took place at Les Pensières, Veyrier-du-Lac, France, from 5 to 16 May 2025. ADVAC is an annual two-week training programme for decision-makers, including academia, industry, governmental and non-governmental agencies. He presented a course on “The role of health economics (including modelling) as a tool in analyzing vaccine policy options”. [ Faculty 2025 ] [ Program ]
Mélanie Drolet presented online to the HPV Steering Committee of the Society of Gynecologic Oncology of Canada (GOC) on April 1st, 2025. The presentation was titled “Potential impact of switching from 2- to 1-dose gender-neutral routine HPV vaccination program in Canada: a mathematical modelling study”.